Research ArticleArticle
One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study
Mark C. Genovese, Patrick Durez, Hanno B. Richards, Jerzy Supronik, Eva Dokoupilova, Jacob A. Aelion, Sang-Heon Lee, Christine E. Codding, Herbert Kellner, Takashi Ikawa, Sophie Hugot, Gregory Ligozio and Shephard Mpofu
The Journal of Rheumatology January 2014, jrheum.130637; DOI: https://doi.org/10.3899/jrheum.130637
Mark C. Genovese
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Patrick Durez
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Hanno B. Richards
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Jerzy Supronik
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Eva Dokoupilova
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Jacob A. Aelion
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Sang-Heon Lee
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Christine E. Codding
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Herbert Kellner
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Takashi Ikawa
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Sophie Hugot
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Gregory Ligozio
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Shephard Mpofu
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Abstract
Objective To evaluate the longer-term safety and efficacy of secukinumab, a fully human monoclonal antiinterleukin-17A antibody, in patients with rheumatoid arthritis.
Methods In this 52-week, double-blind, placebo-controlled (up to Week 20) study (NCT00928512), patients responding inadequately to disease-modifying antirheumatic drugs (DMARD) or biologics were randomized to receive monthly subcutaneous injections of secukinumab (25, 75, 150, or 300 mg), or placebo. The efficacy and safety results up to Week 20 have been reported previously. Here, efficacy results from Week 20 to 52 and safety results from Week 20 to 60 are presented.
Results Of 237 patients randomized, 174 (73.4%) completed the study. Patients with improved American College of Rheumatology (ACR) and 28-joint Disease Activity Score (DAS28) C-reactive protein (CRP) responses at Week 16 sustained their responses through Week 52. In patients taking 150 mg of secukinumab, responses were improved through Week 52 (ACR50: Week 16 = 45%, Week 52 = 55%; DAS28-CRP ≤ 2.6: Week 16 = 25%, Week 52 = 40%). The rate of adverse events (AE) from weeks 20 to 60 was 64.8%, with most AE being mild to moderate in severity. The overall rate of infections was 31.9%, most being mild. The most predominant infection was nasopharyngitis, and was not associated with dose or concurrent neutropenia. Serious AE were reported in 21 patients (8.9%). There were 3 reports of malignancies (ovarian, lung, basal cell), and no deaths between weeks 20 and 60.
Conclusion Patients with active RA who failed to respond to DMARD and other biologics showed an improvement after longterm treatment with 150 mg of secukinumab. The frequency of AE remained stable over time and secukinumab had a consistent safety profile over 60 weeks.
In this issue
The Journal of Rheumatology
Vol. 52, Issue 6
1 Jun 2025
One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study
Mark C. Genovese, Patrick Durez, Hanno B. Richards, Jerzy Supronik, Eva Dokoupilova, Jacob A. Aelion, Sang-Heon Lee, Christine E. Codding, Herbert Kellner, Takashi Ikawa, Sophie Hugot, Gregory Ligozio, Shephard Mpofu
The Journal of Rheumatology Jan 2014, jrheum.130637; DOI: 10.3899/jrheum.130637
One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study
Mark C. Genovese, Patrick Durez, Hanno B. Richards, Jerzy Supronik, Eva Dokoupilova, Jacob A. Aelion, Sang-Heon Lee, Christine E. Codding, Herbert Kellner, Takashi Ikawa, Sophie Hugot, Gregory Ligozio, Shephard Mpofu
The Journal of Rheumatology Jan 2014, jrheum.130637; DOI: 10.3899/jrheum.130637
